Top videos
How to Start an IV Like a Pro (Nursing Skills)
Get the full lesson here: https://nursing.com/lesson/ski....lls-02-01-starting-a
FREE Nursing School Cheat Sheets at: http://www.NURSING.com
Welcome to the NURSING Family, we call it the most supportive nursing cohort on the planet.
At NURSING.com, we want to help you remove the stress and overwhelm of nursing school so that you can focus on becoming an amazing nurse.
Check out our freebies and learn more at: (http://www.nursing.com)
In our Nursing Skills course, we show you the most common and most important skills you will use as a nurse! We included everything from bed baths, to inserting a foley, to advanced skills like chest tube management.
How to Start an IV Like a Pro (Nursing Skills):
This video covers the nursing skill of starting an IV. Here are some tips and tricks to hit that vein every time!
Bookmarks:
0:07 Introduction to starting an IV
0:32 First steps/ Locating a good vein
1:03 Preparing supplies
1:59 Tourniquet replacement
2:11 Cleaning the site
2:26 Inspecting the angiocath
2:46 How to insert the angiocath
3:19 Stabilizing the catheter
3:53 Dressing the catheter
4:19 Labeling the dressing
4:25 Sharps and trash disposal
4:34 Closing words of inspiration
Visit us at http://www.nursing.com/medical-inform... for disclaimer information.
NCLEX®, NCLEX-RN® are registered trademarks of the National Council of State Boards of Nursing, INC. and hold no affiliation with NURSING.com.
A new report analyzing FDA-approved monoclonal antibodies (mAbs) produced by a select group of leading biotechnology companies shows that clinical development times – specifically the duration of Phase II and Phase III trials – are lengthening, while FDA review times have remained constant. The average time from investigational new drug (IND) filing to market was 6.7 years for 11 mABs approved between 1994 and 2003 but shot up to 8.3 years for 12 mAbs approved between 2004 and March 9, 2011, according to Deloitte Recap LLC’s analysis, Therapeutic Monoclonal Antibodies – Insights, Strategies and Data.
Ehlers-Danlos syndrome is a group of disorders that affect the connective tissues that support the skin, bones, blood vessels, and many other organs and tissues. Defects in connective tissues cause the signs and symptoms of Ehlers-Danlos syndrome, which vary from mildly loose joints to life-threatening complications. Previously, there were more than 10 recognized types of Ehlers-Danlos syndrome, differentiated by Roman numerals. In 1997, researchers proposed a simpler classification that reduced the number of major types to six and gave them descriptive names: the classical type (formerly types I and II), the hypermobility type (formerly type III), the vascular type (formerly type IV), the kyphoscoliosis type (formerly type VIA), the arthrochalasia type (formerly types VIIA and VIIB), and the dermatosparaxis type (formerly type VIIC). This six-type classification, known as the Villefranche nomenclature, is still commonly used. The types are distinguished by their signs and symptoms, their underlying genetic causes, and their patterns of inheritance. Since 1997, several additional forms of the condition have been described. These additional forms appear to be rare, affecting a small number of families, and most have not been well characterized.
The average human digestive tract is home to as many as 1,000 species of microorganisms. Most of them are harmless -- or even helpful -- under normal circumstances. But when something upsets the balance of these organisms in your gut, otherwise harmless bacteria can grow out of control and make you sick. One of the worst offenders is a bacterium called Clostridium difficile(C. difficile, or C. diff). As the bacteria overgrow they release toxins that attack the lining of the intestines, causing a condition called Clostridium difficilecolitis.